Aditum Bio

Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for substance use disorders. Its primary focus is on creating transformative therapies, including an orally available metabotropic glutamate receptor (mGluR5) negative allosteric modulator (NAM), designed to regulate neural signaling and treat conditions such as cocaine and alcohol use disorders.

Hubpay is a regulated provider of cross-border money services that aims to expand financial inclusion in emerging markets. It uses data science to create accessible, practical, and affordable everyday financial solutions delivered responsibly to people across income levels. The company offers an online platform for overseas transfers with foreign exchange, multi-currency accounts, collections, and payment systems for suppliers, partners, and employees, enabling instant money transfers and streamlined international settlements. By focusing on compliant and reliable delivery, Hubpay helps businesses operate more efficiently and concentrate on growth while broadening access to cross-border payments.

Via Nova Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics for acute and subacute viral infections that lack effective treatments. The company’s portfolio includes antiviral programs targeting significant respiratory viruses such as influenza, adenoviruses, and rhinoviruses, as well as human polyomaviruses, which can cause severe illness in immunocompromised individuals. By concentrating on the fundamental mechanisms of viral replication, Via Nova Therapeutics aims to facilitate the development of novel therapeutics not only for its current targets but also for a broader range of viral infections.

Versanis Bio is a biopharmaceutical company focused on discovering and developing innovative medicines for medical conditions commonly affecting older adults. The company is advancing Bimagrumab, a human monoclonal antibody that targets activin type II receptors, effectively blocking ligands such as activin A and myostatin. Bimagrumab has undergone extensive clinical evaluation in over a dozen trials with more than 1,500 participants, demonstrating its ability to induce significant fat loss while preserving lean mass. Additionally, treatment with Bimagrumab has shown improvements in HbA1c levels and other cardiometabolic parameters, thereby assisting overweight and obese adults in achieving and maintaining a healthier body composition.

Anteris Bio is developing a new therapy for the treatment of renal disease.